Related Experiment Video
Updated: Jan 20, 2026
Gene Therapy in Disease Intervention
Malignancy and gene therapy in hemophilia
1Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Adeno-associated virus (AAV) gene therapy vectors can integrate into the human genome, posing a theoretical cancer risk. Current evidence does not link AAV integration to human cancers, but robust molecular analysis is crucial for definitive conclusions.
Area of Science:
- Molecular Biology
- Gene Therapy
- Oncology
Background:
- Adeno-associated virus (AAV) vectors are widely used in gene therapy.
- AAV vectors are generally considered nonintegrating but can integrate into the host genome at a low frequency.
- AAV integration theoretically poses a risk for tumorigenesis.
Related Concept Videos
Gene Therapy
08:13Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:32Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
08:34Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
06:11Production and Purification of Baculovirus for Gene Therapy Application

